OBJECTIVES: Bipolar disorder (BPD) affects more than 2 million adults in the USA and ranks among the top 10 causes of worldwide disabilities. Despite its prevalence, very little is known about the etiology of BPD. Recent evidence suggests that cellular energy metabolism is disturbed in BPD. Mitochondrial function is altered, and levels of high-energy phosphates, such as phosphocreatine (PCr), are reduced in the brain. This evidence has led to the hypothesis that deficiencies in energy metabolism could account for some of the pathophysiology observed in BPD. To further explore this hypothesis, we examined levels of creatine kinase (CK) mRNA, the enzyme involved in synthesis and metabolism of PCr, in the hippocampus (HIP) and dorsolateral prefrontal cortex (DLPFC) of control, BPD and schizophrenia subjects. METHODS: Tissue was obtained from the Harvard Brain Tissue Resource Center. Real-time quantitative polymerase chain reaction (HIP, DLPFC) and gene expression microarrays (HIP) were employed to compare the brain and mitochondrial 1 isoforms of CK. RESULTS: Both CK isoforms were downregulated in BPD. Furthermore, mRNA transcripts for oligodendrocyte-specific proteins were downregulated in the DLPFC, whereas the mRNA for the neuron-specific protein microtubule-associated protein 2 was downregulated in the HIP. CONCLUSION: Although some of the downregulation of CK might be explained by cell loss, a more general mechanism seems to be responsible. The downregulation of CK transcripts, if translated into protein levels, could explain the reduction of high-energy phosphates previously observed in BPD.
OBJECTIVES:Bipolar disorder (BPD) affects more than 2 million adults in the USA and ranks among the top 10 causes of worldwide disabilities. Despite its prevalence, very little is known about the etiology of BPD. Recent evidence suggests that cellular energy metabolism is disturbed in BPD. Mitochondrial function is altered, and levels of high-energy phosphates, such as phosphocreatine (PCr), are reduced in the brain. This evidence has led to the hypothesis that deficiencies in energy metabolism could account for some of the pathophysiology observed in BPD. To further explore this hypothesis, we examined levels of creatine kinase (CK) mRNA, the enzyme involved in synthesis and metabolism of PCr, in the hippocampus (HIP) and dorsolateral prefrontal cortex (DLPFC) of control, BPD and schizophrenia subjects. METHODS: Tissue was obtained from the Harvard Brain Tissue Resource Center. Real-time quantitative polymerase chain reaction (HIP, DLPFC) and gene expression microarrays (HIP) were employed to compare the brain and mitochondrial 1 isoforms of CK. RESULTS: Both CK isoforms were downregulated in BPD. Furthermore, mRNA transcripts for oligodendrocyte-specific proteins were downregulated in the DLPFC, whereas the mRNA for the neuron-specific protein microtubule-associated protein 2 was downregulated in the HIP. CONCLUSION: Although some of the downregulation of CK might be explained by cell loss, a more general mechanism seems to be responsible. The downregulation of CK transcripts, if translated into protein levels, could explain the reduction of high-energy phosphates previously observed in BPD.
Authors: R J Hamburg; D L Friedman; E N Olson; T S Ma; M D Cortez; C Goodman; P R Puleo; M B Perryman Journal: J Biol Chem Date: 1990-04-15 Impact factor: 5.157
Authors: Jay W Pettegrew; Joseph Levine; Samuel Gershon; Jeffrey A Stanley; David Servan-Schreiber; Kanagasabai Panchalingam; Richard J McClure Journal: Bipolar Disord Date: 2002-02 Impact factor: 6.744
Authors: Stephen R Dager; Seth D Friedman; Aimee Parow; Christina Demopulos; Andrew L Stoll; In Kyoon Lyoo; David L Dunner; Perry F Renshaw Journal: Arch Gen Psychiatry Date: 2004-05
Authors: Robert M Post; Gabriele S Leverich; Lori L Altshuler; Mark A Frye; Trisha M Suppes; Paul E Keck; Susan L McElroy; Ralph Kupka; Willem A Nolen; Heinz Grunze; Jorg Walden Journal: Bipolar Disord Date: 2003-10 Impact factor: 6.744
Authors: Dhaval Nanavati; Daniel R Austin; Lisa A Catapano; David A Luckenbaugh; Ayse Dosemeci; Husseini K Manji; Guang Chen; Sanford P Markey Journal: J Neurochem Date: 2011-09-21 Impact factor: 5.372
Authors: Xian-Feng Shi; Paul J Carlson; Young-Hoon Sung; Kristen K Fiedler; Lauren N Forrest; Tracy L Hellem; Rebekah S Huber; Seong-Eun Kim; Chun Zuo; Eun-Kee Jeong; Perry F Renshaw; Douglas G Kondo Journal: Bipolar Disord Date: 2015-10-19 Impact factor: 6.744
Authors: Gislaine T Rezin; Camila B Furlanetto; Giselli Scaini; Samira S Valvassori; Cinara L Gonçalves; Gabriela K Ferreira; Isabela C Jeremias; Wilson R Resende; Mariane R Cardoso; Roger B Varela; João Quevedo; Emilio L Streck Journal: Mol Neurobiol Date: 2013-10-15 Impact factor: 5.590
Authors: C Yuksel; F Du; C Ravichandran; J R Goldbach; T Thida; P Lin; B Dora; J Gelda; L O'Connor; S Sehovic; S Gruber; D Ongur; B M Cohen Journal: Mol Psychiatry Date: 2015-03-10 Impact factor: 15.992
Authors: Lara G Chepenik; Fei Wang; Linda Spencer; Marisa Spann; Jessica H Kalmar; Fay Womer; E Kale Edmiston; Brian Pittman; Hilary P Blumberg Journal: Biol Psychol Date: 2012-02-10 Impact factor: 3.251
Authors: K E Borgmann-Winter; N E Rawson; H-Y Wang; H Wang; M L Macdonald; M H Ozdener; K K Yee; G Gomez; J Xu; B Bryant; G Adamek; N Mirza; E Pribitkin; C-G Hahn Journal: Neuroscience Date: 2008-10-17 Impact factor: 3.590
Authors: Lara G Chepenik; Carolyn Fredericks; Xenophon Papademetris; Linda Spencer; Cheryl Lacadie; Fei Wang; Brian Pittman; James S Duncan; Lawrence H Staib; Ronald S Duman; Joel Gelernter; Hilary P Blumberg Journal: Neuropsychopharmacology Date: 2008-08-13 Impact factor: 7.853
Authors: Rafael T de Sousa; Rodrigo Machado-Vieira; Carlos A Zarate; Husseini K Manji Journal: Expert Opin Ther Targets Date: 2014-07-24 Impact factor: 6.902
Authors: Ling Shao; Maureen V Martin; Stanley J Watson; Alan Schatzberg; Huda Akil; Richard M Myers; Edward G Jones; William E Bunney; Marquis P Vawter Journal: Ann Med Date: 2008 Impact factor: 4.709